These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32419534)

  • 1. TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis.
    Gisondi P; Geat D; Conti A; Dapavo P; Piaserico S; De Simone C; Bianchi L; Costanzo A; Malagoli P; Malara G; Micali G; Naldi L; Offidani A; Patrizi A; Prignano F; Parodi A; Rongioletti F; Calzavara-Pinton P; Girolomoni G
    Expert Rev Clin Immunol; 2020 Jun; 16(6):591-598. PubMed ID: 32419534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience.
    Barker J; Girolomoni G; Egeberg A; Goncalves J; Pieper B; Kang T
    J Dermatolog Treat; 2020 Dec; 31(8):794-800. PubMed ID: 31094242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars.
    Prignano F; Choi J; Pieper B; Iversen L
    Expert Opin Biol Ther; 2021 Jan; 21(1):75-80. PubMed ID: 32886008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review.
    Reynolds KA; Pithadia DJ; Lee EB; Han G; Wu JJ
    Expert Opin Drug Saf; 2020 Apr; 19(4):459-466. PubMed ID: 32116071
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.
    Ruda RC; Kelly KA; Feldman SR
    J Dermatolog Treat; 2023 Dec; 34(1):2140569. PubMed ID: 36305624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 10. An overview of developing TNF-α targeted therapy for the treatment of psoriasis.
    Campa M; Ryan C; Menter A
    Expert Opin Investig Drugs; 2015; 24(10):1343-54. PubMed ID: 26289788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
    Zhou X; Chen Z; Bi X
    Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies.
    Numan S; Faccin F
    Adv Ther; 2018 Sep; 35(9):1295-1332. PubMed ID: 30084060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
    Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
    JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single center study.
    Ricceri F; Rosi E; Di Cesare A; Scandagli I; Fastame MT; Prignano F
    J Dermatolog Treat; 2022 Jun; 33(4):1983-1985. PubMed ID: 33929274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
    Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L
    Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.
    Jensen TB; Bartels D; Sædder EA; Poulsen BK; Andersen SE; Christensen MMH; Nielsen L; Christensen HR
    Eur J Clin Pharmacol; 2020 Jan; 76(1):35-40. PubMed ID: 31677117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab for treating plaque psoriasis.
    Rothstein B; Gottlieb A
    Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.